{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T01:47:56Z","timestamp":1781920076815,"version":"3.54.5"},"reference-count":76,"publisher":"Hindawi Limited","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1645,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1111\/j.1529-8019.2011.01396.x","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T15:27:09Z","timestamp":1300202829000},"page":"207-218","source":"Crossref","is-referenced-by-count":59,"title":["Stevens-Johnson syndrome and toxic epidermal necrolysis: a review of treatment options"],"prefix":"10.1155","volume":"24","author":[{"given":"Scott","family":"Worswick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cotliar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"issue":"3","key":"10.1111\/j.1529-8019.2011.01396.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0733-8635(05)70196-0","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Wolkenstein","year":"2000","journal-title":"Dermatol Clin"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jaad.2006.04.048","article-title":"Toxic epidermal necrolysis","volume":"56","author":"Pereira","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1523-1747.2000.00037.x","article-title":"Death receptors in cutaneous biology and disease","volume":"115","author":"Wehrli","year":"2000","journal-title":"J Invest Dermatol"},{"issue":"9140","key":"10.1111\/j.1529-8019.2011.01396.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/00000372-200010000-00005","article-title":"Immunregulatory effector cells in drug-induced toxic epidermal necrolysis","volume":"22","author":"Paquet","year":"2000","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"10.1111\/j.1529-8019.2011.01396.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S1081-1206(10)60789-2","article-title":"Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"97","author":"Khalili","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"10.1111\/j.1529-8019.2011.01396.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.jaci.2004.07.047","article-title":"Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells","volume":"114","author":"Nassif","year":"2004","journal-title":"J All Clin Immunol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1001\/archderm.121.12.1548","article-title":"Plasmapheresis in severe drug-induced toxic epidermal necrolysis","volume":"121","author":"Kamanabroo","year":"1985","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB11|cit11","first-page":"291","volume-title":"Dermatology","author":"Bolognia","year":"2003"},{"issue":"2","key":"10.1111\/j.1529-8019.2011.01396.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1398-9995.2008.01924.x","article-title":"Update on the evaluation of hypersensitivity reactions to beta-lactams","volume":"64","author":"Blanca","year":"2009","journal-title":"Allergy"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB13|cit13","first-page":"103","article-title":"In vitro diagnosis of immediate allergic reactions to drugs: an update","volume":"20","author":"Mayorga","year":"2010","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004630-200021030-00004","article-title":"A 10-year experience with toxic epidermal necrolysis","volume":"21","author":"Schulz","year":"2000","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajo.2009.08.040","article-title":"Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids","volume":"149","author":"Shammas","year":"2010","journal-title":"Am J Ophthamology"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB16|cit16","first-page":"27","article-title":"Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis","volume":"73","author":"Patterson","year":"1994","journal-title":"Ann Allergy"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s004310050561","article-title":"Corticosteroid treatment of erythema multiforme major (Stevens-Johnson syndrome) in children","volume":"156","author":"Kakourou","year":"1997","journal-title":"Eur J Pediatr"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2500\/108854100778250914","article-title":"Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases","volume":"21","author":"Tripathi","year":"2000","journal-title":"Allergy Asthma Proc"},{"issue":"4","key":"10.1111\/j.1529-8019.2011.01396.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/01.iio.0000177430.89645.6d","article-title":"Controversy in the use of high dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome","volume":"45","author":"Hynes","year":"2005","journal-title":"Int J Ophthamol Clin"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB20|cit20","first-page":"537","article-title":"Analysis of treatments and deceased cases of severe adverse drug reactions - analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"58","author":"Yamane","year":"2009","journal-title":"Jpn J Allergol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1046\/j.1365-4362.1997.00100.x","article-title":"Toxic epidermal necrolysis: a retrospective study","volume":"36","author":"Criton","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2340\/00015555-0214","article-title":"Dexamethasone pulse therapy for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"87","author":"Kardaun","year":"2007","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1097\/00004630-199711000-00009","article-title":"Toxic epidermal necrolysis","volume":"18","author":"Engelhardt","year":"1997","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00000658-198611000-00001","article-title":"Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids","volume":"204","author":"Halebian","year":"1986","journal-title":"Ann Surg"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1365-2133.2005.06721.x","article-title":"Toxic epidermal necrolysis: current evidence, practical management and future directions","volume":"153","author":"Chave","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bjps.2004.12.007","article-title":"Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report","volume":"58","author":"Lissia","year":"2005","journal-title":"Br J Plast Surg"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1046\/j.1365-2133.2002.46833.x","article-title":"Antitumor necrosis factor-alpha antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis","volume":"146","author":"Fischer","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.jaci.2005.06.029","article-title":"Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment","volume":"116","author":"Hunger","year":"2005","journal-title":"J All Clin Immunol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1080\/00015550510037062","article-title":"Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab","volume":"85","author":"Al-Shouli","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/j.1468-3083.2006.02026.x","article-title":"Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases","volume":"21","author":"Meiss","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2340\/00015555-0462","article-title":"Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis","volume":"88","author":"Wojtkiewicz","year":"2008","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1346-8138.2009.00616.x","article-title":"Toxic epidermal necrolysis successfully treated with etanercept","volume":"36","author":"Gubinelli","year":"2009","journal-title":"J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/j.1365-4632.2008.04020.x","article-title":"Etanercept in the treatment of a patient with acute generalized exanthematous pustulosis\/toxic epidermal necrolysis: definition of a new model based on translational research","volume":"48","author":"Sadighha","year":"2009","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000048174","article-title":"Intravenous ulinastatin therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis in pediatric patients. Three case reports","volume":"127","author":"Inamo","year":"2002","journal-title":"Int Arch All Immunol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/j.1365-2133.1994.tb13130.x","article-title":"Toxic epidermal necrolysis: treatment with pentoxyfylline","volume":"130","author":"Redondo","year":"1994","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB36|cit36","first-page":"878","article-title":"Pentoxyfylline in toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"38","author":"Clemente","year":"1999","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2133.1997.tb02175.x","article-title":"Drug-induced hypersensitivity syndrome and toxic epidermal necrolysis: treatment with n-acetylcysteine","volume":"136","author":"Redondo","year":"1997","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1067\/mjd.2002.118557","article-title":"Toxic epidermal necrolysis treated with n-acetylcysteine","volume":"46","author":"Velez","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2133.1996.tb01167.x","article-title":"Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis","volume":"135","author":"Goulden","year":"1996","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2230.1997.tb01044.x","article-title":"Toxic epidermal necrolysis treated with cyclosporin and G-CSF","volume":"22","author":"Jarrett","year":"1997","journal-title":"Clin Exp Dermatol"},{"issue":"5Pt1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0190-9622(08)80969-3","article-title":"Efficacy of cyclophosphamide in toxic epidermal necrolysis. clinical and pathophysiologic aspects","volume":"25","author":"Heng","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00007611-199610000-00015","article-title":"Cyclophosphamide in the treatment of toxic epidermal necrolysis","volume":"89","author":"Frangiogiannis","year":"1996","journal-title":"South Med J"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005373-200003000-00017","article-title":"Treatment of toxic epidermal necrolysis with cyclosporin A","volume":"48","author":"Arevalo","year":"2000","journal-title":"J Trauma"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1442-200X.2007.02439.x","article-title":"Toxic epidermal necrolysis in a child successfully treated with cyclosporin A and methylprednisolone","volume":"49","author":"Aihara","year":"2007","journal-title":"Pediatr Int"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-4362.1989.tb02502.x","article-title":"Drug-induced toxic epidermal necrolysis treated with cyclosporin","volume":"28","author":"Renfro","year":"1989","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/039139889101401006","article-title":"Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)","volume":"14","author":"Sakellariou","year":"1991","journal-title":"Int J Artif Organs"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-4362.1997.00192.x","article-title":"Plasmapheresis in toxic epidermal necrolysis","volume":"36","author":"Chaidemenos","year":"1997","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.1998.tb00094.x","article-title":"A study of the efficacy of plasmapheresis for the treatment of drug induced toxic epidermal necrolysis","volume":"2","author":"Yamada","year":"1998","journal-title":"Ther Apher"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/S0190-9622(99)70497-4","article-title":"Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis","volume":"40","author":"Egan","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1046\/j.1526-0968.2002.00409.x","article-title":"Plasma exchange in patients with toxic epidermal necrolysis","volume":"6","author":"Bamichas","year":"2002","journal-title":"Ther Apher"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB51|cit51","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s001340051063","article-title":"Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis?","volume":"25","author":"Furubacke","year":"1999","journal-title":"Intensive Care Med"},{"issue":"5388","key":"10.1111\/j.1529-8019.2011.01396.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of cd95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1440-0960.1999.00347.x","article-title":"Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin","volume":"40","author":"Phan","year":"1999","journal-title":"Australas J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB54|cit54","first-page":"2494","article-title":"Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome","volume":"27","author":"Morici","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome: experience with high-dose intravenous immunoglobulins and topical conservative approach: a retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1067\/mjd.2002.127249","article-title":"Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children","volume":"47","author":"Tristani-Firouzi","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB57|cit57","first-page":"430","article-title":"High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis","volume":"83","author":"Campione","year":"2003","journal-title":"Acta Derm Venereol"},{"issue":"6Pt1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1542\/peds.112.6.1430","article-title":"Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature","volume":"112","author":"Metry","year":"2003","journal-title":"Pediatrics"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archderm.139.1.26","article-title":"Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases","volume":"139","author":"Prins","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB60|cit60","first-page":"1117","article-title":"Prospective non-comparative open study from Kuwait of the role of intravenous immunoglobulin in the treatment of toxic epidermal necrolysis","volume":"43","author":"Al-Mutari","year":"2004","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB61|cit61","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1346-8138.2005.tb00704.x","article-title":"High dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series","volume":"32","author":"Tan","year":"2005","journal-title":"J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"398","DOI":"10.4103\/0378-6323.18943","article-title":"Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study","volume":"71","author":"Mangla","year":"2005","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00000441-200502000-00007","article-title":"Intravenous immunoglobulin for treatment of toxic epidermal necrolysis","volume":"329","author":"Nasser","year":"2005","journal-title":"Am J Med Sci"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.sder.2006.04.004","article-title":"Toxic epidermal necrolysis and intravenous immunoglobulin: a review","volume":"25","author":"Trent","year":"2006","journal-title":"Seminars Cutaneous Medicine Surgery"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2165\/00128071-200607060-00004","article-title":"Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"7","author":"Mittmann","year":"2006","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB66|cit66","first-page":"29","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options","volume":"50","author":"Teo","year":"2009","journal-title":"Singapore Med J"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB67|cit67","first-page":"383","article-title":"Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens-Johnson\/toxic epidermal necrolysis overlap syndrome. review of 15 cases","volume":"137","author":"Molgo","year":"2009","journal-title":"Rev Med Chil"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/j.1365-4632.2006.02833.x","article-title":"Intravenous immunoglobulin in toxic epidermal necrolysis","volume":"45","author":"Pasic","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.2165\/00003495-200565150-00002","article-title":"Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IVIG): clinical experience to date","volume":"65","author":"Faye","year":"2005","journal-title":"Drugs"},{"issue":"1","key":"10.1111\/j.1529-8019.2011.01396.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatment on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1529-8019.2011.01396.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1001\/archderm.139.1.85","article-title":"Treatment of toxic epidermal necrolysis","volume":"139","author":"Wolff","year":"2003","journal-title":"Arch Dermatol"},{"issue":"15","key":"10.1111\/j.1529-8019.2011.01396.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1517\/14656566.2010.515587","article-title":"Topical treatment options for drug-induced toxic epidermal necrolysis (TEN)","volume":"11","author":"Paquet","year":"2010","journal-title":"Expert Opin Pharmacother"}],"container-title":["Dermatologic Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1529-8019.2011.01396.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1529-8019.2011.01396.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T05:25:54Z","timestamp":1712294754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1529-8019.2011.01396.x"}},"subtitle":["SJS\/TEN: review of treatment options"],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1529-8019.2011.01396.x","relation":{},"ISSN":["1396-0296"],"issn-type":[{"value":"1396-0296","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}